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Abstract
Introduction: Secretory products from adipocytes may contribute to deterioration in glycaemic control and increased insulin resistance
(IR). Retinol-binding protein 4 (RBP-4) may increase IR in mice, with elevated levels in insulin-resistant mice and humans with obesity and
type 2 diabetes. However, the mechanisms regulating RBP-4 synthesis remain not fully understood. It is not clear whether short-term
glucose-induced hyperglycaemia and hyperinsulinaemia as well as glucocorticosteroid-induced increase in IR might be reflected in altera-
tions in serum RBP-4 levels in humans. In order to investigate this, we measured serum RBP-4, glucose and insulin concentrations during
75.0 gram oral glucose tolerance test (OGTT) — Study 1, as well as before and after oral administration of dexamethasone — Study 2.
Material and methods: Both studies included 35 subjects (8 males), age (mean ± SD) 39.1 ± 15.6 years, BMI 35.8 ± 8.7 kg/m2. Twenty-four
of those subjects (5 males), age 38.7 ± 15.1 years, BMI 34.4 ± 8.3 kg/m2, had 75 gram oral glucose tolerance test (OGTT) — Study 1. Blood
samples were taken before (0 minutes), and at 60 and 120 minutes of OGTT. 17 subjects (3 males, 4 subjects with type 2 diabetes), age
43.1 ± 18.1 years, BMI 36.7 ± 9.0 kg/m2 underwent screening for Cushing’s disease/syndrome (Study 2). Dexamethasone was administered
in a dose of 0.5 mg every 6 hours for 48 hours. Fasting serum concentrations of RBP-4, glucose and insulin were assessed before (D0) and
after 48 hours of dexamethasone administration (D2). IR was assessed by HOMA in all non-diabetic subjects and in subjects participating
in study 1 also by Insulin Resistance Index (IRI), which takes into account glucose and insulin levels during OGTT.
Results: Glucose administration resulted in significant increases in insulin and glucose (p < 0.0001). There was, however, no change
in RBP-4 concentrations (124.1 ± 32 mg/ml at 0 minutes, 123 ± 35 mg/ml at 60 minutes and 126.5 ± 37.5 mg/ml at 120 minutes of OGTT, p = ns).
All subjects in Study 2 achieved suppression of cortisol below 50 nmo/l. Dexamethasone administration resulted in an increase in fasting
insulin (from 11.6 ± 6.8 to 17.1 ± 7.2 µU/ml; p = 0.003), and an increase in HOMA (from 2.73 ± 1.74 to 4.02 ± 2.27; p = 0.015), although
without a significant change in RBP-4 levels (119 ± 26.8 vs. 117.5 ± 24.8 mg/ml, p = ns). RBP-4 correlated with fasting insulin (r = 0.40,
p = 0.025), fasting glucose (r = 0.41, p = 0.02) and HOMA (r = 0.43, p = 0.015), but not with IRI (r = 0.19, p = 0.31). There was, however,
only a moderate correlation between HOMA and IRI (r = 0.49 [r2 = 0.24]; p = 0.006, Spearman rank correlation), while the best correlation
was obtained between the product of glucose and insulin levels at 60 min of OGTT and IRI in a non-linear model (r = 0.94 [r2 = 0.88];
p<0.00001). In subjects who received dexamethasone, a positive correlation between RBP-4 and HOMA (p = 0.01) was lost after two days
of dexamethasone administration (p = 0.61).
Conclusions: RBP-4 levels do not change during oral glucose tolerance test or after a dexamethasone-induced increase in insulin resistan-
ce. This implies that it is highly unlikely that RBP-4 is involved in short-term regulation of glucose homeostasis in humans and that
it responds to short-term changes in insulin resistance. A moderate correlation between RBP-4 and some insulin resistance indices (HOMA)
does not exclude the fact that RBP-4 might be one of many factors that can influence insulin sensitivity in humans. (Pol J Endocrinol 2008;
59 (4): 305–311)
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Streszczenie
Wstęp: Niektóre substancje syntetyzowane przez adipocyty mogą zwiększać insulinooporność oraz nasilać zaburzenia tolerancji gluko-
zy. Białko wiążące retinol 4 (RBP-4) nasila insulinooporność u myszy, zaś podwyższone stężenia RBP-4 obserwuje się u myszy z insulino-
opornością oraz u osób z otyłością i cukrzycą typu 2. Mechanizmy regulujące syntezę RBP-4 nie są do końca poznane. Między innymi nie
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Secretory products from adipocytes may contribute to
deterioration in glycaemic control and increased insu-
lin resistance (IR), with complications such as type 2
diabetes, atherosclerosis and sympathetic activation [1–3].
Retinol-binding protein-4 (RBP-4) is a protein that is the
specific carrier for retinol (vitamin A alcohol) in the blo-
od, described in 1987 [4]. RBP-4 is normally bound to
transthyretin in the circulation. Its physiological func-
tion appears to be to bind retinol and prevent its loss
through the kidneys. Recent studies suggested that
RBP-4, an adipose-derived adipocytokine, may also in-
crease IR [5], with elevated levels in insulin-resistant
mice and humans with obesity and type 2 diabetes
[5, 6]. Genetic deletion of RBP-4 enhances insulin sensi-
tivity, whilst increased serum levels of RBP-4 not only
impair insulin signalling in muscle, but also augment
hepatic gluconeogenesis [5]. The first aim of our study
was to determine whether RBP-4 levels change after
short-term glucose-induced hyperinsulinaemia and to
determine whether RBP-4 might be involved in short-
term, (i.e. postprandial) regulation of glycaemia in hu-
mans. The second aim of our study was to determine
whether there is a correlation between serum RBP-4
concentrations and insulin resistance indices and whe-
ther a change in insulin resistance might alter serum
RBP-4 levels. It has long been known that glucocortico-
steroids cause insulin resistance in vitro and in vivo [7]
primarily due to a post-receptor effect [8]. Hence, we
have also endeavoured to determine whether gluco-
corticosteroid-induced change in insulin resistance mi-
ght influence serum RBP-4 levels.
Material and methods
The study included 35 subjects (8 males), age (mean ±
± SD) 39.1 ± 15.6 years, BMI 35.8 ± 8.7 kg/m2. Obese or
overweight patients at risk of diabetes or impaired glu-
cose tolerance were recruited either from the Obesity
and Metabolic Clinic of the “Polish Mother” Memorial
Research Institute (Instytut Centrum Zdrowia Matki
Polki w Łodzi) or from a general practice - “Your Fami-
ly Doctor” Group Practice, Lodz (NZOZ “Twój Lekarz
Rodzinny” sp, Socjalna 48, 93–324 Lodz). Twenty-four
of those subjects (19 females and 5 males, age 38.7 ± 15.1
years, BMI 34.4 ± 8.3 kg/m2 ) had an oral glucose tole-
rance test (OGTT) performed according to the World
Health Organization (WHO) standard [9] — Study 1.
Serum samples were taken before (0 minutes) and at
60 and 120 minutes after ingestion of a solution conta-
ining 75.0 g glucose.
Seventeen subjects (14 females, 3 males), including
4 persons with type 2 diabetes mellitus (all insulin-treated),
age 43.1 ± 18.1 years, BMI 36.7 ± 9.0 kg/m2, had serum
concentration of RBP-4, glucose, insulin and cortisol as-
sessed before (D0) and after 48 hours (D2) of administra-
tion of dexamethasone (0.5 mg every 6 hours for 48 ho-
wiadomo czy krótkotrwała hiperglikemia i hiperinsulinemia po podaniu glukozy, jak również zwiększona insulinooporność wyidukowa-
na glukokortykosteroidami mogą w istotny sposób zmienić stężenie RBP-4 w surowicy u ludzi. W związku z tym autorzy artykułu ocenili
stężenie RBP-4, glukozy i insuliny w teście doustnego obciążenia glukozą (75 g) (OGTT) — badanie 1, oraz przed i po doustnym podaniu
deksametazonu — badanie 2.
Materiał i metody: W obu badaniach uczestniczyło 35 osób (8 mężczyzn) w wieku 39,1 ± 15,6 lat, BMI 35,8 ± 8,7 kg/m2 (średnia ± SD).
Spośród nich u 24 osób (5 mężczyzn) w wieku 38,7 ± 15,1 lat, BMI 34,4 ± 8,3 kg/m2 wykonano OGTT (badanie 1). Krew pobierano przed
(0 minuta) oraz w 60. i 120. minucie OGTT. Badanie 2 objęło 17 osób (3 mężczyzn, 4 osoby z cukrzycą typu 2) poddanych badaniu przesie-
wowemu pod kątem choroby/zespołu Cushinga w wieku 43,1 ± 18,1 lat, BMI 36,7 ± 9,0 kg/m2. Deksametazon podawano co 6 godzin
w dawce 0,5 mg przez 48 godzin. Stężenia RBP-4, glukozy i insuliny w surowicy oznaczono na czczo przed (D0) i po 48 godzinach
podawania deksametazonu (D2). U osób niechorujących na cukrzycę IR oceniano metodą HOMA, zaś w badaniu 1 również według
Insulin Resistance Index (IRI) obliczanego na podstawie zmian stężeń insuliny i glukozy podczas OGTT.
Wyniki: Podczas OGTT w badaniu 1 wzrosły stężenia insuliny i glukozy (p < 0,001), przy braku istotnych zmian stężeń RBP-4 (124,1 ± 32  mg/ml
w 0 min, 123 ± 35 mg/ml w 60. min i 126,5 ± 37,5 mg/ml w 120. min OGTT, p = ns). W badaniu 2 u wszystkich osób uzyskano supresję
stężenia kortyzolu do wartości poniżej 50 nmo/l. Skutkiem podania deksametazonu był wzrost stężeń insuliny na czczo (z 11,6 ± 6,8 do
17,1 ± 7,2 µU/ml; p = 0,003) oraz wzrost współczynnika HOMA (z 2,73 ± 1,74 do 4,02 ± 2,27; p = 0,015). Nie zaobserwowano jednak
istotnych zmian stężeń RBP-4 (119 ± 26,8 mg/ml vs. 117,5 ± 24,8 mg/ml, p = ns). Stężenia RBP-4 korelowały z insulinemią na czczo (r = 0,40,
p = 0,025), glukozą na czczo (r = 0,41, p = 0,02) oraz z HOMA (r = 0,43, p = 0,015), lecz już nie z IRI (r = 0,19, p = 0,31). Stwierdzono
obecność korelacji pomiedzy indeksami insulinooporności HOMA i IRI (r = 0.49 [r2 = 0,24], p = 0,006, współczynnik korelacji rang Spear-
mana), lecz znacznie silniejszą korelację obserwowano dopiero miedzy IRI a iloczynem stężeń insuliny i glukozy w 60. minucie OGTT
(r = 0,94 [r2 = 0,88]; p<0,0001). Dopasowany do zależności tych zmiennych model nieliniowy (funkcja kwadratowa) wyjaśniał 88-procen-
towe zmienności, podczas gdy model liniowy 70%. U osób, które otrzymały deksametazon dodatnia korelacja między steżeniami RBP-4
i HOMA (p = 0,01) nie była już obserwowana po dwóch dniach przyjmowania deksametazonu (p = 0,61).
Wnioski: Stężenia RBP-4 nie zmieniają się w doustnym teście tolerancji glukozy oraz po nasileniu insulinooporności w wyniku podania
deksametazonu. Jest zatem mało prawdopodobne, aby RBP-4 odgrywało istotną rolę w regulacji poposiłkowych glikemii oraz miało
wpływ na krótkotrwałe zmiany insulinooporności. Umiarkowana korelacja pomiędzy RBP-4 oraz niektórymi wskaźnikami insulinoopor-
ności (HOMA) nie wyklucza jednak, że RBP-4 może być jednym z wielu czynników wpływających na regulację insulinooporności u ludzi.
(Endokrinol Pol 2008; 59 (4): 305–311)
Słowa kluczowe: retinol-binding protein 4, tolerancja glukozy, deksametazon, insulinooporność
307













urs) during screening for Cushing’s disease/syndrome
(Study 2). Non-diabetic individuals (n = 31) had insulin
resistance assessed according to the HOMA method
(where HOMA = fasting insulin concentration [µU/ml]
¥ fasting glucose concentration [mmol/l] / 22.5) [10], while
those subjects who had an OGTT (Study 1, n = 24) also
had insulin resistance assessed by Insulin Resistance In-
dex (IRI), i.e. a method based on changes of glycaemia
and insulinaemia during OGTT. IRI was calculated using
the formula: 2/[1/(INSp x GLYp)]+1, where INSp and
GLYp are the measured insulin and glycaemic areas [11,
12]. Serum RBP-4 was measured by commercial RBP-4
assay kit (Phoenix Pharmaceuticals Inc., intra-assay va-
riation < 5%, inter-assay variation < 14%). Insulin was
measured by ELISA (DakoCytomation Ltd, Denmark
House, Angel Drove, Ely CB7 4 ET, UK), while plasma
glucose was measured by standard hexokinase method.
The study protocol was approved by the Ethics Com-
mittee of the Medical University of Lodz (Poland).
Statistical analysis
In both studies, the data were analysed by means of
simple descriptive statistics and non-parametric tests of
significance - the Wilcoxon matched-paired test for com-
parison of distributions of particular parameters in dif-
ferent OGTT time intervals. In study 2, the data were
also analysed by paired t-test, given the normal distri-
bution of the variables. Associations between RBP-4
concentrations and other parameters were assessed by
the Spearman rank correlation method. In all analyses,
statistical significance was considered achieved for
a value of p £ 0.05. All the calculations were derived by
means of Statistica v. 6.0 software.
Results
The main results of Study 1 are presented in Table I. There
was a significant increase in glucose and insulin concen-
trations during OGTT, although without significant chan-
ge in serum RBP-4 concentration (124 ± 32.2 mg/ml vs.
123 ± 35.1 mg/ml and 126.5 ± 37.5 mg/ml at 0, 60 and
120 minutes of OGTT, respectively, p = ns). The results
of Study 2 are presented in Table II. Administration of
dexamethasone for 48 hours resulted in a significant in-
crease in fasting insulin (11.6 ± 6.8 vs. 17.1 ± 7.2 µU/ml,
p = 0.003) and HOMA index (2.73 ± 1.74 vs. 4.02 ± 2.28,
p = 0.015), indicative of an increase in insulin resistance.
Again, there was no change in serum RBP-4 concentra-
tion (119.0 ± 26.8 mg/ml vs. 117.5 ± 24.8mg/ml, p = ns).
Correlation analysis between serum RBP-4 levels
and other covariates, analysed jointly for subjects par-
ticipating in studies 1 and 2, is presented in Table III.
There was a moderate but significant positive correla-
tion between RBP-4 and fasting insulin (r = 0.401,
p = 0.025, Figure 1A), fasting glucose (r = 0.411, p = 0.022)
and HOMA (r = 0.432, p = 0.015, Figure 1B), without
significant correlation with other parameters including
age, BMI, lipids and IRI. In subjects who received dexa-
methasone, a positive correlation between RBP-4 and
HOMA (r = 0.45, p = 0.01) was lost after two days of
dexamethasone administration (p = 0.61).
Simultaneously, however, there was a significant
correlation between HOMA and IRI (i.e. r = 0.49;
p = 0.0002) for Spearman rank correlation coefficient.
In this model, however, a variation of HOMA explained
only 24% of variation of IRI (Figure 2A). A non-linear
(quadratic) model fitted to the mentioned relation be-
tween HOMA and IRI explained 43% of the variation
Table I. Descriptive statistics for the levels of insulin, RBP-4 and glucose during 75 gram oral glucose tolerance test (OGTT) in
24 subjects participating in Study 1. P-value represents the significance level of the Wilcoxon matched-paired test for comparison
of distributions of these characteristics in different OGTT time intervals
Tabela I. Stężenia insuliny, RBP-4 oraz glukozy podczas 75-gramowego doustnego testu tolerancji glukozy (OGTT) u 24 osób
uczestniczących w badaniu 1. Wartość P oznacza istotność statystyczną w teście Wilcoxona dla par zmiennych przy porównaniu
ich rozkładów w kolejnych punktach czasowych OGTT
Parameter OGTT Mean 95%CI  Mean Med SD Min Max P value
RBP-4 [mg/ml] 0’ 124.1 (113.0; 135.1) 118.8 32.2 58.0 200.0 0 ÷ 60’ 0.57
60’ 123.0 (108.2; 137.8) 120.9 35.1 72.8 199.0 60 ÷ 120’ 0.44
120’ 126.5 (110.7; 142.3) 129.6 37.5 51.6 200.0 0 ÷ 120’ 0.81
Glucose [mg/dl] 0’ 90.4 (84.2; 96.7) 85.0 17.0 72.0 150.0 0 ÷ 60’ 0.000002
60’ 158.3 (139.0; 177.7) 152.0 51.8 82.0 297.0 60 ÷ 120’ 0.00001
120’ 120.5 (103.8; 137.2) 113.0 45.6 61.0 295.0 0 ÷120’ 0.0001
Insulin [mU/ml] 0’ 11.6 (9.1; 14.2) 9.5 7.0 2.1 29.5 0 ÷ 60’ 0.000001
60’ 98.0 (76.47; 119.7) 77.0 59.1 19.7 222.0 60 ÷ 120’ 0.13
120’ 82.6 (63.4; 101.7) 75.3 52.3 11.9 186.0 0 ÷ 120’ 0.000001
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Table II. Concentrations of RBP-4 and other parameters before (D0) and after 48 hours of administration of dexamethasone
(D2) in 17 subjects participating in study 2. Dexamethasone was administered orally in a dose of 0.5 mg every 6 hours for 48
hours. P-value represents the significance level of the Wilcoxon matched-paired test for comparison of distributions of these
characteristics before (D0) and after administration of dexamethasone (D2)
Tabela II. Stężenia RBP-4 oraz insuliny i glukozy na czczo oraz HOMA przed (D0) oraz po 48 godzinach przyjmowania
deksametazonu (D2) u 17 pacjentów uczestniczących w badaniu 2. Deksametazon był podawany w dawce 0,5 mg co 6 godzin
przez 48 godzin. Wartość P oznacza istotność statystyczną w teście Wilcoxona dla par zmiennych przy porównaniu ich rozkładów
przed (D0) oraz po podaniu deksametazonu (D2)
Parameter D0 (mean ± SD) D2 (mean ± SD) P value
RBP-4 [mg/ml] 119.0 ± 26.8 117.5 ± 24.8 0.76
Glucose [mg/dl]* 92.9 ± 21.0 93.8 ± 19.8 0.62
Insulin [mU/ml] 11.6 ± 6.8 17.1 ± 7.2 0.003
HOMA**
(glucose [mmol/l]·insulin [µU/ml]/22.5) 2.73 ± 1.74 4.02 ± 2.28 0.015
*In order to convert mg/dl into mmol/l for plasma glucose, divide by 18
**HOMA calculated for non-diabetic individuals (n = 15)
Table III. Spearman rank correlation coefficients for the association between RBP-4 and other covariates in all subjects
participating in Study 1 and Study 2
Tabela III. Współczynniki korelacji rang Spearmana między stężeniami RBP-4 oraz innymi zmiennymi analizowanymi łącznie
dla wszystkich pacjentów uczestniczących w badaniach 1 i 2
Parameter N rs P value
Fasting insulin (all non-diabetic subjects) 31 0.401 0.025
Fasting glucose 35 0.411 0.022
HOMA (all non-diabetic subjects) 31 0.432 0.015
IRI 24 0.192 0.301
Triglycerides 35 0.079 0.674
Total cholesterol 35 –0.232 0.201
LDL cholesterol 31 –0.328 0.095
HDL cholesterol 31 –0.113 0.544
BMI 35 0.203 0.241
Age 35 –0.112 0.522
(Figure 2B). The strongest correlation was observed be-
tween IRI and glucosexinsulin product at 60 minutes of
OGTT (r = 0.94; p < 0.00001, Figure 2C) and glucose-
xinsulin product at 120 minutes of OGTT (r = 0.84;
p < 0.00001, Figure 2D). In a fitted quadratic model, the
product of concentrations of glucose and insulin at
60 minutes of OGTT explained over 88% of the varia-
tion in IRI (Figure 2C), while the product of glucose and
insulin concentrations at 120 minutes of OGTT expla-
ined 74% of the variation. In contrast, the product of
fasting glucose and fasting insulin concentrations used
for the calculation of the HOMA index was able to expla-
in only 24% or 43% of the variation of Insulin Resistance
Index, depending on the model used (Figures 2A and 2B).
There was also a positive correlation between IRI and
BMI (0.431, p = 0.015).
Discussion
Our studies demonstrate that RBP-4 concentrations do
not change during the oral glucose tolerance test in
humans. This implies that RBP-4 does not seem to be
involved in short-term, i.e. postprandial regulation of
glycaemia in human subjects. Our study also indicates
that an increase in insulin resistance, induced by dexa-
methasone, does not result in any appreciable change
in serum RBP-4 levels. To the best of our knowledge,
this is the first study in which the direct effects of glu-
cocorticosteroids on serum RBP-4 levels have been as-
sessed in this context in humans. The results of our stu-
dy are in contrast to the data obtained in rats, where
dexamethasone increased serum RBP-4 levels after
7 days of administration of very high doses of dexame-
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thasone (0.5 mg/kg/day) [13]. In our opinion, these data
might not be applicable to human subjects as this wo-
uld correspond to enormous doses of dexamethasone
(around 40 to 60 mg per day in humans), where the
pharmacological effects of such high doses of glucocor-
ticosteroids might be mediated through effects other
than insulin resistance. We acknowledge, however, that
full assessment of the effects of dexamethasone on se-
rum RBP-4 levels might require RBP-4 measurements
after administration of higher doses of dexamethaso-
ne, taking into account that maximal doses (e.g. used in
Figure 1A. Correlation between serum RBP-4 and fasting insulin
as assessed by the Spearman rank correlation coefficient (n = 31)
(r = 0.401, p = 0.025)
Rycina 1A. Korelacja między stężeniami RBP-4 w surowicy krwi
a insulinemią na czczo oceniana według współczynnika korelacji
rang Spearmana (n = 31; r = 0,401; p = 0,025)
Figure 1B. Correlation between serum RBP-4 levels (n = 31)
and HOMA in individuals not taking insulin (n = 31), r = 0.432,
p = 0.015
Rycina 1B. Korelacja między stężeniami RBP-4 w surowicy krwi
a insulinoopornością ocenianą według wskaźnika HOMA (n =
31; r = 0,432; p = 0,015
Figure 2A. Correlation between insulin resistance indices i.e.
HOMA and Insulin Resistance Index (IRI) in a linear model
(r2 = 0.24; p = 0.006). This indicates that in a linear model the
variability of the HOMA index explains only 24% of the variability
of IRI. The HOMA index is calculated as a product of fasting
insulin concentration [µU/mL] and fasting glucose concentration
[mmol/L] / 22,5 [10], while the IRI method is based on changes in
glycaemia and insulinaemia not only in a fasting state, but also at
60 and 120 minutes of 75 gram OGTT. The precise method of IRI
calculation is described in [11, 12]
Rycina 2A. Zależność pomiędzy wskaźnikiem insulinooporności
HOMA i Insulin Resistance Index (IRI), w niewielkim tylko
stopniu wyjaśniona w modelu liniowym (r2 = 0.24; p = 0.006).
Oznacza to, że zmiany wartości HOMA pozwalają wyjaśnić
jedynie 24% zmienności parametru IRI w modelu liniowym.
Wskaźnik HOMA jest obliczony według wzoru: stężenie insuliny
na czczo [µU/ml] ¥ stężenie glukozy na czczo [mmol/l]/22,5 [10],
zaś wskaźnik IRI wykorzystuje ocenę nie tylko glikemii
i insulinemii na czczo, lecz również w 60. i 120. minucie doustnego
testu tolerancji glukozy (75 gram). Szczegółowy sposób obliczenia
wskaźnika IRI opisano w pozycjach piśmiennictwa 11 i 12
Figure 2B. Correlation between HOMA and IRI in a non-linear
model (r2 = 0.43; p = 0.00004). In this model the variability of
the HOMA index explains only 43% of the variation of IRI
Rycina 2B. Zależność między HOMA a IRI w modelu nieliniowym
(r2 = 0,43; p = 0,00004). Oznacza to, że w modelu nieliniowym
zmiany wartości HOMA wyjaśnia 43% zmienności parametru IRI
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vels were slightly lower in insulin-resistant subjects in
comparison to controls, and increased following further
dilutions of the sera. The authors suggest, however, that
there is a possibility that the results of other studies may
also be fraught with similar methodological problems,
when concentrations of RBP-4 are so high that they fall
significantly outside the linear range of the standard cu-
rve of the particular assay system.
Further problems may pertain to the different me-
thodology of the assessment of IR. For instance, Gra-
ham et al. [6] assessed IR by the means of a clamp study
i.e. according to the glucose disposal rate during the last
30 minutes of the clamp, as recommended by DeFron-
zo et al. [20], although the correlation with fasting insu-
lin was also assessed. Takashima et al. [15] assessed the
correlation between RBP-4 and fasting insulin, Erikstrup
et al. [16] assessed IR by means of HOMA index, while
Borengasser-Yao et al. [17] assessed insulin sensitivity
by means of an insulin-modified frequently sampled iv
cases of cerebral oedema) generally do not exceed
24 mg/24 hours.
So far, several studies [6, 14–16] have demonstrated
raised RBP-4 levels in non-pregnant subjects with IR and/
/or type 2 diabetes. However, the assessment of the rela-
tionship between RBP-4 and IR yielded very discrepant
results. Graham et al. [6] demonstrated a relationship
between serum RBP-4 and insulin resistance. On the
other hand, other researches [15, 16] have not found
a correlation between serum levels of RBP-4 and insulin
resistance indices. Some authors [17] have suggested the
lack of a correlation between RBP-4 and insulin sensiti-
vity, but a positive correlation between serum RBP-4 and
some inflammatory markers. Interestingly, this is in con-
trast to other studies in which acute (but not chronic)
inflammation was associated with decreased RBP-4 con-
centrations [18]. In our opinion, several factors may con-
tribute to such diverse results as to the correlation be-
tween RBP-4 and IR. Graham et al. [19] have recently
speculated that the lack of a correlation between RBP-4
and IR in some studies may result from problems with
some RBP-4 ELISA assays, where high RBP-4 levels mi-
ght be reported as falsely low as a result of antibody sa-
turation. This applied particularly to one of the assay
systems (Scimedx, Denville, NJ, USA), where RBP-4 le-
Figure 2D. Positive correlation between IRI and the product of
glucose [mmol/L] and insulin [µU/mL] concentrations at
120 minutes of the OGTT explained by non-linear model (r2 = 0.71;
p<0.00001). In this model the variability of glucose and insulin
product at 60 minutes of OGTT explains 71% of the variation of
IRI. Although this is slightly less than at 60 min of OGTT, the
product of glucose and insulin concentrations at 120 minutes of
OGTT still explains the variability of IRI to a much greater degree
that the HOMA index based on the product of fasting glucose and
insulin concentrations
Rycina 2D. Dodatnia korelacja między IRI a iloczynem stężeń
glukozy [mmol/l] i insuliny [µU/ml] w 120. minucie OGTT
opisana modelem nieliniowym (r2 = 0,71; p < 0,00001). W tym
modelu zmienność iloczynu stężeń glukozy i insuliny w 120 minucie
OGTT wyjaśnia 71% zmienności parametru IRI. Oznacza to, że
zmienność iloczynu stężeń insuliny i glukozy w 120. minucie
OGTT wyjaśnia w nieco mniejszym stopniu zmienność IRI niż
zmiany iloczynu stężeń glukozy i insuliny w 60. minucie OGTT,
ale i tak wyjaśnia to zmienność IRI w dużo większym stopniu
zmienność indeksu HOMA, który opiera się na iloczynie stężeń
glukozy i insuliny na czczo
Figure 2C. Correlation between IRI and the product of glucose
[mmol/L] and insulin concentrations [µU/mL] at 60 minutes of
the OGTT explained by nonlinear model (r2 = 0.88; p<0.00001).
In this model the variability of glucose and insulin product at
60 minutes of OGTT explains 88% of the variation of IRI, i.e. to
a much greater degree than the HOMA index based on the product
of fasting glucose and insulin concentrations
Rycina 2C. Silna dodatnia korelacja między IRI a iloczynem
stężeń glukozy [mmol/l] i insuliny [µU/ml] w 60. minucie OGTT
opisana modelem nieliniowym (r2 = 0,88; p < 0,00001). W tym
modelu zmienność iloczynu stężeń glukozy i insuliny w 60.
minucie OGTT wyjaśnia 88% zmienności parametru IRI, czyli
znacznie więcej niż zmienność indeksu HOMA, który opiera się
na iloczynie stężeń glukozy i insuliny na czczo
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glucose tolerance test using 11.4 g/m2 — glucose and
0.04 U/kg — insulin, according to the method descri-
bed by Bergman et al. [21].
Our results demonstrate a moderate correlation be-
tween RBP-4 and HOMA, but not with IRI, i.e. with
a static (based on fasting glucose and insulin), but not
a dynamic (i.e. based on both fasting and post-glucose
load levels) index of IR. Such a situation is not surpri-
sing, given that the lack of any significant change of
serum RBP-4 concentrations contrasted with increases
in glucose and insulin levels during OGTT. Similar to
the study of Graham et al. [6], we have also found
a correlation between RBP-4 and fasting insulin. Inte-
restingly, however, the correlation between HOMA in-
dex (which is based on a product of fasting glucose and
fasting insulin concentrations) and IRI, although signi-
ficant, is not particularly strong (Figure 2A). This is im-
proved in a non-linear model (Figure 2B), but it only
becomes highly significant when a product of glucose
and insulin concentrations at 60 minutes of OGTT, ra-
ther than a HOMA index, is used in a non-linear model
(Figure 2C). In addition, a linear model for the depen-
dence between HOMA and IRI explains only 24% of
the variation of the Insulin Resistance Index (r2 = 0.24;
p = 0.006, Figure 2A). Hence, it is highly likely that some
methods used to calculate IR may fail to demonstrate
a relationship between RBP-4 and insulin sensitivity be-
cause there is only a moderate correlation between the
methods of the assessment of insulin resistance based
on fasting glucose and insulin concentrations vs. the
methods that account for glucose and insulin excursions
after glucose stimulation. Other authors [22] also com-
ment on the relative weakness of a correlation between
HOMA and insulin resistance indices based on OGTT.
Furthermore, Diamanti-Kandarakis et al. [23] demon-
strated rather a weak correlation between HOMA and
QUICKI (the quantitative insulin sensitivity check in-
dex) and the assessment of insulin sensitivity by a eu-
glycaemic clamp technique in women with polycystic
ovary syndrome. The authors concluded that mathe-
matical indices should be applied with caution in diffe-
rent insulin-resistant populations and should not be
considered a priori equivalent to the euglycaemic clamp
technique, i.e. to the “golden standard” for the asses-
sment of insulin sensitivity.
In summary, our study demonstrates a moderate
correlation between serum RBP-4 concentrations and
fasting insulin as well as the HOMA index. There was,
however, no change in serum RBP-4 concentrations
after OGTT or after a dexamethasone-induced increase
in insulin resistance. This implies that, even though
RBP-4 might be one of many factors potentially invo-
lved in regulation of insulin sensitivity in humans, the
changes of serum RBP-4 concentrations are unlikely to
influence postprandial glycaemia and are unlikely to
be involved in the pathogenesis of glucocorticosteroid-
induced insulin resistance.
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